NEW YORK, Sept 28 — Biogen Inc was set to add more than US$10 billion to its market capitalisation today, as a surprise trial success of the experimental Alzheimer’s drug it developed with Eisai was hailed as an unequivocal win by analysts.
Biogen’s stock surged 35.4 per cent to US$267.61 in early US trading, putting it on track to erase all of its losses this year. Shares of Japan’s Eisai Co Ltd jumped 17 per cent to the daily limit in Tokyo.Biogen and Eisai said their experimental drug, lecanemab, slowed progress of the brain-wasting disease by 27 per cent compared with a placebo, in a large trial of patients in the early stages of Alzheimer’s.
This so-called amyloid hypothesis suffered a particularly heavy blow last year, after US regulators overruled their own panel of outside experts to approve another Biogen drug called Aduhelm, based on its plaque-clearing ability rather than proof that it helped slow cognitive decline.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaysiakini - 🏆 20. / 51 Read more »
Source: malaysiakini - 🏆 20. / 51 Read more »
Source: malaymail - 🏆 1. / 86 Read more »
Source: malaymail - 🏆 1. / 86 Read more »
Source: malaymail - 🏆 1. / 86 Read more »
Source: malaymail - 🏆 1. / 86 Read more »